Sarton E, Olofsen E, Romberg R, den Hartigh J, Kest B, Nieuwenhuijs D, Burm A, Teppema L, Dahan A
Departments of Anesthesiology, Clinical Pharmacy and Toxicology, and Physiology, Leiden University Medical Center, Leiden, The Netherlands.
Anesthesiology. 2000 Nov;93(5):1245-54; discussion 6A. doi: 10.1097/00000542-200011000-00018.
Animal and human studies indicate the existence of important sex-related differences in opioid-mediated behavior. In this study the authors examined the influence of morphine on experimentally induced pain in healthy male and female volunteers.
Young healthy men and women (10 of each sex) received intravenous morphine (bolus 0.1-mg/kg dose followed by an infusion of 0.030 mg. kg-1. h-1 for 1 h). Pain threshold and pain tolerance in response to a gradual increase in transcutaneous electrical stimulation, as well as plasma concentrations of morphine and its major metabolites (morphine-6-glucuronide and morphine-3-glucuronide) were determined at regular intervals up to 7 h after the start of morphine infusion. A population pharmacodynamic model was used to analyze the morphine-induced changes in stimulus intensity. The improvement of the model fits by inclusion of covariates (sex, age, weight, lean body mass) was tested for significance. The model is characterized by baseline current, a rate constant for equilibrium between plasma and effect-site morphine concentrations (ke0), and analgesic potency (AC50, or the morphine concentration causing a 100% increase in stimulus intensity for response).
The inclusion of the covariates age, weight, and lean body mass did not improve the model fits for any of the model parameters. For both pain threshold and tolerance, a significant dependency on sex was observed for the parameters ke0 (pain threshold: 0.0070 +/- 0.0013 (+/- SE) min-1 in men vs. 0.0030 +/- 0. 0005 min-1 in women; pain tolerance: 0.0073 +/- 0.0012 min-1 in men vs. 0.0024 +/- 0.0005 min-1 in women) and AC50 (pain threshold: 71.2 +/- 10.5 nm in men vs. 41.7 +/- 8.4 nm in women; pain tolerance: 76. 5 +/- 7.4 nm in men vs. 32.9 +/- 7.9 nm in women). Baseline currents were similar for both sexes: 21.4 +/- 1.6 mA for pain threshold and 39.1 +/- 2.3 mA for pain tolerance. Concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide did not differ between men and women.
These data show sex differences in morphine analgesia, with greater morphine potency but slower speed of onset and offset in women. The data are in agreement with observations of sex differences in morphine-induced respiratory depression and may explain higher postoperative opioid consumption in men relative to women.
动物和人体研究表明,阿片类药物介导的行为存在重要的性别差异。在本研究中,作者研究了吗啡对健康男性和女性志愿者实验性诱导疼痛的影响。
年轻健康男性和女性(各10名)静脉注射吗啡(初始剂量0.1mg/kg,随后以0.030mg·kg-1·h-1的速度输注1小时)。在吗啡输注开始后长达7小时的时间内,定期测定经皮电刺激逐渐增加时的疼痛阈值和疼痛耐受性,以及吗啡及其主要代谢产物(吗啡-6-葡萄糖醛酸苷和吗啡-3-葡萄糖醛酸苷)的血浆浓度。使用群体药效学模型分析吗啡诱导的刺激强度变化。通过纳入协变量(性别、年龄、体重、瘦体重)来检验模型拟合度的改善是否具有显著性。该模型的特征包括基线电流、血浆和效应部位吗啡浓度平衡的速率常数(ke0)以及镇痛效力(AC50,即导致反应刺激强度增加100%的吗啡浓度)。
纳入协变量年龄、体重和瘦体重并未改善任何模型参数的模型拟合度。对于疼痛阈值和耐受性,在ke0参数(疼痛阈值:男性为0.0070±0.0013(±标准误)min-1,女性为0.0030±0.0005min-1;疼痛耐受性:男性为0.0073±0.0012min-1,女性为0.0024±0.0005min-1)和AC50参数(疼痛阈值:男性为71.2±10.5nm,女性为41.7±8.4nm;疼痛耐受性:男性为76.5±7.4nm,女性为32.9±7.9nm)方面,观察到对性别的显著依赖性。两性的基线电流相似:疼痛阈值为21.4±1.6mA,疼痛耐受性为39.1±2.3mA。男性和女性的吗啡、吗啡-3-葡萄糖醛酸苷和吗啡-6-葡萄糖醛酸苷浓度无差异。
这些数据表明吗啡镇痛存在性别差异,女性吗啡效力更高,但起效和消退速度较慢。这些数据与吗啡诱导的呼吸抑制中的性别差异观察结果一致,可能解释了男性术后阿片类药物消耗量相对于女性更高的原因。